Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 26.25
Bid: 25.50
Ask: 27.00
Change: -1.00 (-3.67%)
Spread: 1.50 (5.882%)
Open: 26.75
High: 26.75
Low: 26.25
Prev. Close: 27.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Bank of Cyprus swings profit; Sareum loss widens

Mon, 21st Feb 2022 18:13

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Bank of Cyprus Holdings PLC - Nicosia-based lender - Reports turnover of EUR755.2 million for 2021, down from EUR765.1 million in 2020. Despite this, swings to pretax profit of EUR36.1 million from loss of EUR166.9 million. Is helped by sharply reduced credit losses to cover credit risk on loans and advances to customers, booking expense of EUR40.3 million in 2021 versus charge of EUR275.1 million in 2020. "2021 saw a strong recovery in the Cypriot economy after a period of pandemic-related disruption, providing an improved backdrop against which the Bank performed well. During the year we continued to support the country's return to growth, extending EUR1.8 bn of new loans, an increase of a third on the prior year and steadily recovering towards pre-pandemic levels," says Chief Executive Panicos Nicolaou. Looking ahead, now targets return on tangible equity in medium-term in excess of 10%, "providing the foundations for a return of dividend distributions, subject to performance and relevant approvals."

----------

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Pretax loss for six months to December 31 widens to GBP1.0 million from GBP610,000 year-on-year, with no revenue generated in either period. Says it is looking to 2022 with optimism and expects to report on continued progress both with its proprietary programmes, in particular the advancement of SDC-1801 into clinical trials, and with partnered asset, SRA737, should Sierra advance its development. "The board and management also continue to employ rigorous capital allocation in the development of internal assets and the overall business, with a clear focus on generating value for shareholders," firm says.

----------

Sylvania Platinum Ltd - Bermuda-based platinum group metals producer - Revenue for six months to end of December falls to USD69.1 million from USD84.9 million, while pretax profit drops to USD34.9 million from USD57.4 million. Sylvania Dump Operations delivered 32,376 4E PGM ounces, down from 36,335 ounces a year ago. Notes lower than planned run of mine and current arising PGM feed grades at the Western operations affected production, as well as temporary suspension of operations at Lesedi extended through the first quarter and, subsequent to start-up, the plant incurred further downtime related to general water shortages at the Western operations during the second quarter. Declares windfall dividend of 2.25 pence, to be paid in April. "Based on the progress that we are making with the Lesedi MF2, which we plan to commission in March, as well as the provisional results from targeted sampling campaigns and investigations to evaluate potential alternative feed sources to mitigate current low ROM feed grades at Mooinooi, we are expecting a stronger production performance during HY2 FY2022," says Chief Executive Jaco Prinsloo.

----------

Graft Polymer (UK) PLC - Slovenia-based polymer modification and drug delivery systems - Expects an increase in commercial orders following successful trials. To meet demand, firm has moved to a two-shift operation at its Slovenia production facility to ensure order fulfilment. Full production capacity at the existing facilities is results in an output of 4,000 tonnes of product per year. "This is in line with the strategy of investing in additional equipment at its facility to increase the production capabilities as set out in the IPO prospectus. These investments will allow the Company to increase its current production output to 6,000 tonnes per annum," firm says. Adds that Slovenian Intellectual Property Office has awarded company four new patents.

----------

Cellular Goods PLC - London-based cannabinoid product company - After strategy review, says it will exclusively focus on wellness products across its three market verticals, being skincare, supplements and recovery. Says initial sales of inaugural products have been below internal forecasts due to "market challenges". "The company has identified various factors that negatively impacted sales, including a policy decision by some of the world's largest social media companies. Google, and Meta's platforms Facebook and Instagram, prohibit advertising cannabis-derived products, which has prevented the company's products from being promoted there," firm says. Has made changes to media mix for its upcoming marketing campaign. Says it has accelerated retail partnerships and has launched Look Better range on Amazon Marketplace.

----------

Immotion Group PLC - Manchester, England-based virtual reality entertainment company - Says second half revenue was around GBP6.6 million, more than double the GBP2.8 million in the first half of the year. Second half operating cash inflow was strong, with year-end cash on hand of GBP1.1 million, almost double the GBP600,000 at the half year. "Overall, we feel we have made good progress across the company and are looking forward with renewed confidence," says Chief Executive Martin Higginson. Adds that it has got contract extension and expansion of capacity at Shark Reef Aquarium, inside Mandalay Bay Resort & Casino, Las Vegas, currently the group's largest installation. This will see the theatre capacity increase to 48 seats from its current 36 seats, and the contract will be extended by a further 12 months through to January 31, 2024. Says that in addition, capacity at another two of its strongest performing sites has been "significantly expanded".

----------

Allied Minds PLC - Boston, Massachusetts-based intellectual property commercialisation company - Says portfolio company Federated Wireless has secured USD58 million in Series D funding at a pre new-money valuation of USD230 million. Allied Minds participates in fundraise, alongside an affiliate of Cerberus Capital Management LP and GIC, Singapore's sovereign wealth fund. "We're proud of the achievements made by Federated Wireless, which have been recognised by investors in this well-backed funding round," says Chair Harry Rein. Adds that Mark Pritchard, founder and former executive chair of Allied Minds and a 5.5% shareholder, has been appointed as a consultant to the board.

----------

BiVictriX Therapeutics PLC - Macclesfield, England-based drug development company specialising in cancer treatments - Files four new patent applications in the UK related to several novel cancer-specific antigen pairs or "fingerprints" across a range of oncology indications. These applications focus on three novel cancer-specific antigen fingerprints that have been identified by the company and can support the development of a pipeline of highly selective cancer therapeutics utilising the company's Bi-Cygni approach. "These filings are the next step in the company's strategy to broaden its patent portfolio both in the UK and internationally," it says.

----------

Polar Capital Global Financials Trust PLC - London-based financial investor - Plans to raise additional funds through share issue as interest in company "remains high" and appetite for shares "has not diminished". To issue new shares at a placing price to be published on the day following the closing date of the placing. "The directors and Polar Capital LLP continue to believe that the company is well positioned to benefit from higher interest rates, rising inflation expectations and stronger economic growth given the significant exposure of the portfolio to banks in particular," firm says.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 Dec 2023 14:31

UK shareholder meetings calendar - next 7 days

Friday 8 December 
Amedeo Air Four Plus LtdAGM
Ashoka India Equity Investment Trust PLCAGM
Associated British Engineering PLCAGM
Associated British Foods PLCAGM
Corcel PLCGM re disposal of 41% interest in the Mambare nickel/cobalt project
Hargreaves Lansdown PLCAGM
URA Holdings PLCGM re closing the fundraise
Monday 11 December 
IamFire PLCAGM with vote on name change to WeCap PLC
Pharma C Investments PLCGM re allowing investments in fintech, AI sectors
SigmaRoc PLCGM re reverse takeover
Tribal Group PLCGM re cash offer by Tiger Bidco 1 Ltd
Vela Technologies PLCAGM
Tuesday 12 December 
Atalaya Mining PLCEGM re redomiciliation to Spain from Cyprus
Blackrock Greater Europe Investment Trust PLCAGM
Distil PLCGM re placing and subscription
Gelion PLCAGM
Wednesday 13 December 
Dechra Pharmaceuticals PLCAGM
Limitless Earth PLCAGM
Softcat PLCAGM
Volution Group PLCAGM
Thursday 14 December 
Aeorema Communications PLCAGM
CleanTech Lithium PLCGM re equity raise approval
Driver Group PLCFull Year Results
eEnergy Group PLCAGM
Ethernity Networks LtdGM re authority to allot shares on non-preemptive basis
Fintech Asia LtdAGM
Helium One Global LtdAGM
Marwyn Value Investors LtdAGM
Quarto Group IncGM re cancelling trading on London's Main Market
Sareum Holdings PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
23 Nov 2023 14:28

IN BRIEF: Sareum Holdings draws down on equity prepayment facility

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the GBP300,000 second deposit in respect of a previously announced equity prepayment facility.

Read more
9 Nov 2023 13:47

EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 Nov 2023 13:59

Sareum secures Japan patent for kinase inhibitor asset

(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.

Read more
3 Nov 2023 09:01

Sareum says patent notice in Japan boosts confidence in SDC-1801

(Alliance News) - Sareum Holdings PLC on Friday said it received a notice of allowance from Japan's Patent Office for a patent relating to its lead TYK2/JAK1 kinase inhibitor, SDC-1801.

Read more
9 Oct 2023 15:06

Sareum losses widen as clinical trials continue

(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.

Read more
9 Oct 2023 10:58

Sareum says earnings down but product development going well

(Alliance News) - Sareum Holdings PLC on Monday said its annual loss widened and its cash reserves are substantially reduced, but that development and testing of its medicinal products is progressing well.

Read more
6 Sep 2023 14:35

Director dealings: Blackbird, Sareum insiders pick up shares

(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.

Read more
4 Sep 2023 09:18

Sareum begins dosing participants in phase 1a trial for SDC-1801

(Alliance News) - Sareum Holdings PLC on Monday said it has successfully started the multiple ascending dose part of its phase 1a clinical trial for its SDC-1801 drug, following approval from the safety review committee.

Read more
16 Aug 2023 13:13

Sareum flagship drug trial progressing well ahead of annual results

(Alliance News) - Sareum Holdings PLC on Wednesday said a clinical trial for its main therapeutic is continuing as planned, and it hopes to use a new prepayment facility to further enhance development.

Read more
3 Aug 2023 14:16

IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs.

Read more
26 Jun 2023 17:33

TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News:

Read more
26 Jun 2023 10:54

Sareum granted new patents in China, US

(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.

Read more
6 Jun 2023 13:36

IN BRIEF: Sareum doses first subjects in psoriasis drug trial

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.